-
Nov 17, 2026 Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes
-
Nov 12, 2026 Apotex Announces Second Quarter 2027 Results
-
Oct 9, 2026 Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
-
Oct 5, 2026 Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
-
Sep 29, 2026 Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
-
Sep 18, 2026 Apotex Health Corp. announces closing of upsized bought deal secondary offering
-
Sep 15, 2026 Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
-
Sep 15, 2026 Apotex Health Corp. announces $750 million bought deal secondary offering
-
Aug 12, 2026 Apotex Announces First Quarter 2027 Results
-
Jul 17, 2026 Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
-
Jul 1, 2026 Apotex completes previously announced strategic transaction with Cumberland Pharmaceuticals
-
Jun 30, 2026 Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management
-
Jun 16, 2026 Apotex Health Corp. announces closing of upsized initial public offering and exercise of over-allotment option in full
-
Jun 10, 2026 Apotex Health Corp. files final prospectus and announces pricing of upsized initial public offering
-
Jun 9, 2026 Apotex Health Corp. upsizes its initial public offering
-
Jun 1, 2026 Apotex Health Corp. launches its initial public offering
-
May 28, 2026 Apotex Health Corp. files preliminary prospectus for initial public offering
-
May 26, 2026 Apotex expands ophthalmic portfolio with Health Canada approval of IHEEZO™
-
May 14, 2026 Apotex launches Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada
-
May 1, 2026 Apotex becomes the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Nov 17, 2026
Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes
TORONTO, ON, November 16, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced the launch of APO-LINAGLIPTIN™ (linagliptin tablets), the latest addition to its portfolio of medicines.
-
Nov 12, 2026
Apotex Announces Second Quarter 2027 Results
TORONTO, ON, November 12, 2026 – Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), a Canadian-based global health company and Canada’s largest pharmaceutical company, today announced its financial and operating results for the three and six months ended September 30, 2026. All financial figures are in Canadian dollars unless otherwise indicated.
-
Oct 9, 2026
Apotex to announce second quarter fiscal 2027 financial results and host conference call on Nov. 12, 2026
TORONTO, Oct. 8, 2026 /CNW/ -- Apotex Health Corp.("Apotex") (TSX: APTX) today announced that it will issue a press release with its second quarter Fiscal 2027 financial results on Thursday, November 12, 2026, at approximately 6:00 a.m. ET. Apotex will host a conference call and live webcast to discuss the results at 8:00a.m. ET.